Paul Mahon Sells 11,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• Paul Mahon, EVP of United Therapeutics, sold 11,000 shares of the company's stock for a total of $4,746,500.00, reducing his ownership by 23.02% to 36,781 shares.
• United Therapeutics reported quarterly earnings of $6.41 EPS, missing expectations by $0.39 while generating $798.60 million in revenue, a year-over-year increase of 11.7%.
• Analysts have shown optimism, with targets for UTHR stock price ranging from $525.00 to $580.00 following recent upgrades, maintaining a consensus rating of "Moderate Buy".

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 11,000 shares of the business's stock in a transaction that occurred on Thursday, October 16th. The shares were sold at an average price of $431.50, for a total transaction of $4,746,500.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company's stock, valued at $15,871,001.50. The trade was a 23.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

United Therapeutics Price Performance

UTHR stock traded down $12.56 during midday trading on Monday, reaching $420.78. 122,969 shares of the stock were exchanged, compared to its average volume of 591,945. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $459.48. The company has a fifty day moving average price of $385.69 and a 200 day moving average price of $328.19. The stock has a market capitalization of $18.98 billion, a PE ratio of 16.47, a P/E/G ratio of 4.72 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same quarter last year, the firm posted $5.85 earnings per share. The business's revenue for the quarter was up 11.7% on a year-over-year basis. As a group, analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on UTHR shares. UBS Group increased their price objective on shares of United Therapeutics from $560.00 to $580.00 and gave the stock a "buy" rating in a research report on Monday, September 29th. Jefferies Financial Group increased their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a research note on Tuesday, September 2nd. Weiss Ratings reissued a "hold (c+)" rating on shares of United Therapeutics in a research note on Wednesday, October 8th. Oppenheimer increased their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research note on Friday, September 5th. Finally, Cantor Fitzgerald increased their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 10th. Ten analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, United Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $457.21.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Chung Wu Investment Group LLC acquired a new position in shares of United Therapeutics in the 2nd quarter worth approximately $29,000. WealthCollab LLC boosted its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its stake in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 46 shares during the last quarter. SVB Wealth LLC bought a new stake in shares of United Therapeutics in the 1st quarter valued at $32,000. Finally, Geneos Wealth Management Inc. increased its holdings in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 85 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.